Background: It is important to differentiate low-grade malignant peripheral nerve sheath tumors (MPNSTs) from benign nerve sheath tumors as MPNSTs may require a more aggressive treatment strategy during and after initial resection. Loss of expression of the trimethyl histone H3 at the Lys27 position (H3K27-me3) has recently been described in MPNSTs and may help distinguish this tumor from pathologic mimics.

Methods: A 43-year-old woman presented with symptoms of radiculopathy and a history of pelvic radiation for cervical cancer 7 years prior. Imaging and surgical pathology were initially consistent with an L5 schwannoma including spindle morphology without mitoses and retained S100 expression. After an aggressive recurrence 11 months later, pathology was consistent with high-grade MPNST including heightened mitotic activity and loss of S100 expression.

Results: After the identification of MPNST, H3K27M me3 immunostaining was applied to both the initial and recurrent pathologic specimens. The initial specimen demonstrated patchy loss of H3K27M me3 expression, more consistent with low-grade MPNST than schwannoma.

Conclusion: This case highlights the role of H3K27M me3 immunostaining to help differentiate MPNSTs that may mimic more benign nerve sheath tumors, especially in patients who have a history of radiation to the region in question.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.06.035DOI Listing

Publication Analysis

Top Keywords

nerve sheath
16
sheath tumors
12
h3k27m me3
12
low-grade malignant
8
malignant peripheral
8
peripheral nerve
8
tumors mpnsts
8
benign nerve
8
me3 immunostaining
8
nerve
4

Similar Publications

NF1 encodes the multifunctional tumour suppressor protein, neurofibromin, which is best known for its causative role in Neurofibromatosis type 1 and in regulating MAPK signaling. Neurofibromin, in a context-specific manner, is involved in various tumorigenic processes, including those in melanocytes. This study investigated whether NF1 loss can collaborate with oncogenic GNAQ to promote melanoma in the dermis or eyes, where the G alpha q pathway is almost always activated.

View Article and Find Full Text PDF

Subclavian Ansae Stimulation on Cardiac Hemodynamics and Electrophysiology in Atrial Fibrillation: A Target for Sympathetic Neuromodulation.

JACC Clin Electrophysiol

December 2024

St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom; William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. Electronic address:

Background: The sympathetic autonomic nervous system plays a major role in arrhythmia development and maintenance. Historical preclinical studies describe preferential increases in cardiac sympathetic tone upon selective stimulation of the subclavian ansae (SA), a nerve cord encircling the subclavian artery.

Objectives: This study sought to define, for the first time, the functional anatomy and physiology of the SA in humans using a percutaneous approach.

View Article and Find Full Text PDF

Background: Plexiform neurofibromas (PNs) are histologically benign peripheral nerve sheath tumors associated with neurofibromatosis type 1 (NF1) and often lead to significant morbidity due to growth. Management includes watchful waiting, surgery for partial debulking, and, since recently, systemic treatment with MEK inhibitors. However, due to the scarcity of natural history studies, our understanding of the natural progression of PNs to guide clinicians in deciding in whom and when to intervene is scarce.

View Article and Find Full Text PDF

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and the primary cause of mortality in patients with neurofibromatosis type 1 (NF1). These malignancies develop within preexisting benign lesions called plexiform neurofibromas (PNs). PNs are solely driven by biallelic loss eliciting RAS pathway activation, and they respond favorably to MEK inhibitor therapy.

View Article and Find Full Text PDF

Purpose: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma that develops sporadically or in Neurofibromatosis type 1 patients. Its development is marked by the inactivation of specific tumor suppressor genes (TSGs): NF1, CDKN2A and SUZ12EED (Polycomb Repressor Complex 2). Each TSG loss can be targeted by particular drug inhibitors and we aimed to systematically combine these inhibitors, guided by TSG inactivation status, to test their precision medicine potential for MPNSTs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!